Jingwei Lu

Title: Innovations and Contributions of Inventor Jingwei Lu

Introduction

Jingwei Lu is a prominent inventor based in Union City, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody agents and chimeric constructs. With a total of 7 patents to his name, Lu's work has the potential to impact therapeutic treatments for various diseases.

Latest Patents

One of his latest patents is titled "Antibody agents specific for human CD19 and uses thereof." This patent describes human antibody agents and multi-specific binding agents that specifically bind to human CD19, particularly the native form. The patent also outlines methods for using these agents in the detection, prevention, and therapeutic treatment of diseases characterized by CD19 expression, such as B cell lymphomas and leukemias. Another notable patent is "Antibody/T-cell receptor chimeric constructs and uses thereof." This application provides antibody-TCR chimeric constructs that comprise an antibody moiety specifically binding to a target antigen, fused to a TCRM capable of recruiting at least one TCR-associated signaling module. The patent includes methods for making and using these constructs.

Career Highlights

Jingwei Lu is currently associated with Eureka Therapeutics, Inc., where he continues to innovate and develop groundbreaking technologies. His work at Eureka Therapeutics has positioned him as a key player in the biotechnology sector, focusing on advanced therapeutic solutions.

Collaborations

Lu collaborates with talented individuals in his field, including Zhiyuan Yang and Hong Liu. These collaborations enhance the research and development efforts at Eureka Therapeutics, fostering an environment of innovation and discovery.

Conclusion

Jingwei Lu's contributions to biotechnology through his patents and work at Eureka Therapeutics highlight his role as an influential inventor. His innovative approaches to antibody agents and chimeric constructs are paving the way for advancements in therapeutic treatments.